BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY
BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF FIELD TRIAL FOR LARGE-SCALE IMMUNOCONTRACEPTION IN THE COMMERCIAL AQUATIC FARMING INDUSTRY
Initial research field trials were started this spring in the Pacific Northwest. "We've been focused on developing vaccines to help manage free-ranging populations of animals like horses and deer, so this is an exciting new venture for us", said Dr. Bechert, Vice President of Research and Development for SpayVac-for-Wildlife, Inc. VANCOUVER, BC, and MADISON, Wis. , April 10, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac-for-Wildlife, Inc. ("SpayVac") jointly announce that SpayVac has partnered with a world leader in the aquaculture space to field test single-injection, long-lasting immuno-contraceptive vaccines in farmed rainbow trout.
不列颠哥伦比亚省温哥华和威斯康星州麦迪逊，2024年4月10日 /PRNewswire/ — BioVaxys Technology Corp.（CSE：BIOV）（FRA：5LB）（OTCQB：BVAXF）（“BioVaxys”）（“BioVaxys”）和 SpayVac-for-Wildlife, Inc.（“SpayVax”）共同宣布，SpayVac已与水产养殖领域的全球领导者合作进行单次注射实地测试，用于养殖虹鳟的长效免疫避孕疫苗。
SpayVac utilizes a patented liposome-based antigen delivery platform technology licensed from BioVaxys ( and has demonstrated a robust and sustained immune response in several species.
SpayVac采用了BioVaxys许可的基于脂质体的抗原递送平台专利技术（并已在多个物种中显示出强大而持续的免疫反应。
Large-scale contraception or sterilization plays a major role in the commercial aquaculture industry. As female fish mature, they put the majority of their energy into egg production, instead of muscle growth, which reduces the potential weight gain. Additionally, farm-raised fish that escape may breed with their wild counterparts and produce offspring that are less suited to surviving in the wild. Growing reproductively contracepted or sterile fish is the most effective way to manage these challenges.
大规模避孕或绝育在商业水产养殖业中起着重要作用。随着雌鱼的成熟，它们将大部分能量用于产卵，而不是肌肉生长，这会减少潜在的体重增加。此外，逃跑的农场养殖的鱼类可能会与野生鱼类一起繁殖，并产生不太适合在野外生存的后代。种植生殖避孕或不育鱼类是应对这些挑战的最有效方法。
Initial research field trials were started this spring in the Pacific Northwest. "We've been focused on developing vaccines to help manage free-ranging populations of animals like horses and deer, so this is an exciting new venture for us", said Dr. Bechert, Vice President of Research and Development for SpayVac-for-Wildlife, Inc.
初步的研究实地试验于今年春天在太平洋西北地区开始。Spayvac-for-Wildlife, Inc.研发副总裁Bechert博士说：“我们一直专注于开发疫苗，以帮助管理马和鹿等自由放养的动物种群，因此这对我们来说是一项令人兴奋的新事业。”
In addition to fish aquaculture, SpayVac is planning to soon commercialize humane fertility control vaccines for deer, horses and other animals that are also based on the patented liposome-based delivery platform technology licensed from BioVaxys.
除了鱼类水产养殖外，SpayVac计划很快将针对鹿、马和其他动物的人道生育控制疫苗商业化，这些疫苗也基于BioVaxys许可的基于脂质体的专利输送平台技术。
James Passin, BioVaxys CEO, stated, "We are excited at the recent progress of our licensee, SpayVac-for-Wildlife, Inc., in advancing its fish immunocontraception research. The global market for farmed fish is estimated to exceed $306,000,000,0001. We look forward to continuing to support the important work of our partner SpayVac in the field of animal fertility vaccines."
BioVaxys首席执行官詹姆斯·帕辛表示：“我们对我们的被许可方SpayVac-for-Wildlife, Inc.最近在推进鱼类免疫避孕研究方面取得的进展感到兴奋。据估计，全球养殖鱼类市场超过3.06亿美元1。我们期待继续支持我们的合作伙伴SpayVac在动物生育疫苗领域的重要工作。”
1 EMR Claight, Global Fish Farming Market Size, Share, Trends, Forecast 2023, 2024
1 EMR Claight， 2023、2024年全球鱼类养殖市场规模、份额、趋势、预测
About SpayVac-for-Wildlife, Inc.
关于 Spayvac-for-Wildlife, Inc.
SpayVac-for-Wildlife, Inc., ( based in Madison, Wisconsin, develops humane fertility-control vaccines for animals. SpayVac contraceptive vaccines are effective in a variety of species for multiple years with just a single injection. For questions about this research or SpayVac in general, please email [email protected].
Spayvac-for-Wildlife, Inc.（总部位于威斯康星州麦迪逊）为动物开发人性化生育控制疫苗。SpayVac 避孕疫苗只需注射一次即可对多种物种有效多年。如对这项研究或一般的SpayVac有任何疑问，请发送电子邮件至 [email protected]。
About BioVaxys Technology Corp.
关于 BioVaxys 科技公司
BioVaxys Technology Corp. (), a biopharmaceutical company registered in British Columbia, Canada, is a clinical-stage company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and it's HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company's clinical stage pipeline includes maveropepimut-S, a DPX-based vaccine which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, DPX-RSV for Respiratory Syncytial Virus, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.
BioVaxys Technology Corp. () 是一家在加拿大不列颠哥伦比亚省注册的生物制药公司，是一家临床阶段的公司，致力于通过基于DPX免疫教育技术平台及其Haptenix “新抗原” 肿瘤细胞构建平台的新型免疫疗法改善患者生活，用于治疗癌症、传染病、抗原脱敏和其他免疫学领域。该公司的临床阶段产品线包括基于DPX的疫苗MaveropePimut-S，目前正处于晚期复发难治性弥漫性大B细胞淋巴瘤（DLBCL）和耐铂卵巢癌的二期临床开发、用于呼吸道合胞病毒的DPX-RSV以及使用其专有的 Haptenix “新抗原” 肿瘤细胞构建平台的个性化免疫治疗疫苗 BVX-0918 即将进入西班牙治疗屈光晚期卵巢癌的第一阶段。该公司还利用其肿瘤免疫学专业知识，利用其个性化免疫治疗疫苗创建了独特的T淋巴细胞和其他数据集库，以利用预测算法和其他技术来识别新的可靶向肿瘤抗原。
BioVaxys common shares are listed on the CSE under the stock symbol "BIOV" and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).
BioVaxys的普通股在CSE上市，股票代码为 “BIOV”，并在法兰克福证券交易所（FRA：5LB）和美国（场外交易代码：BVAXF）上市。
ON BEHALF OF THE BOARD
代表董事会
Signed "James Passin"
James Passin, CEO
BioVaxys Technology Corp.
+1 646 452 7054
签名 “詹姆斯·帕森”
首席执行官詹姆斯·帕森
BioVaxys 科技公司
+1 646 452 7054
ON BEHALF OF THE BOARD
代表董事会
Signed "Dr. Ursula Bechert"
Dr. Ursula Bechert
SpayVac-for-Wildlife, Inc.
+1 877 510 6812
签名 “厄休拉·贝歇特博士”
厄休拉·贝切特博士
Spayvac-for-Wildlife, Inc.
+1 877 510 6812
Logo -
徽标-
SOURCE BioVaxys Technology Corporation
来源 bioVaxys 科技公司
